Clinical trial
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia…
NCT00098839 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00098839 |
|---|---|
| Title | Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) |
| Official title | A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL) |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Childhood Acute Lymphoblastic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate and 4 more |
| Enrollment | 134 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Dec 9, 2004 |
| Last update posted | Dec 12, 2017 |
| Countries | Australia, Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: